Skip to main content
SpringerLink
Log in

Antiestrogens: Mechanisms of action and resistance in breast cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Antiestrogens have proven to be highly effective in the treatment of hormone-responsive breast cancer. However, resistance to antiestrogen therapy often develops. In addition, although tamoxifen-like antiestrogens are largely inhibitory and function as estrogen antagonists in breast cancer cells, they also have some estrogen-like activity in other cells of the body. Thus, recent efforts are being directed toward the development of even more tissue-selective antiestrogens, i.e. compounds that are antiestrogenic on breast and uterus while maintaining the beneficial estrogen-like actions on bone and the cardiovascular system. Efforts are also being directed toward understanding ligand structure-estrogen receptor (ER) activity relationships and characterizing the molecular changes that underlie alterations in parallel signal transduction pathways that impact on the ER. Recent findings show that antiestrogens, which are known to exert most of their effects through the ER of breast cancer cells, contact a different set of amino acids in the hormone binding domain of the ER than those contacted by estrogen, and evoke a different receptor conformation that results in reduced or no transcriptional activity on most genes.

Resistance to antiestrogen therapy may develop due to changes at the level of the ER itself, and at pre- and post-receptor points in the estrogen receptor-response pathway. Resistance could arise in at least four ways: (1) ER loss or mutation; (2) Post-receptor alterations including changes in cAMP and phosphorylation pathways, or changes in coregulator and transcription factor interactions that affect the transcriptional activity of the ER; (3) Changes in growth factor production/sensitivity or paracrine cell-cell interactions; or (4) Pharmacological changes in the antiestrogen itself, including altered uptake and retention or metabolism of the antiestrogen. Model cell systems have been developed to study changes that accompany and define the antiestrogen resistant versus sensitive breast cancer phenotype. This information should lead to the development of antiestrogens with optimized tissue selectivity and agents to which resistance may develop more slowly. In addition, antiestrogens which work through somewhat different mechanisms of interaction with the ER should prove useful in treatment of some breast cancers that become resistant to a different category of antiestrogens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Katzenellenbogen BS, Fang H, Ince BA, Pakdel F, Reese JC, Wooge CH, Wrenn CK: Estrogen receptors: Ligand discrimination and antiestrogen action. Breast Cancer Res Treat 27:17–26, 1993

    Google Scholar 

  2. Katzenellenbogen BS, Montano M, Le Goff P, Schodin DJ, Kraus WL, Bhardwaj B, Fujimoto N: Antiestrogens: Mechanisms and actions in target cells. J Steroid Biochem Molec Biol 53:387–393, 1995

    Google Scholar 

  3. Osborne CK, Elledge RM, Fuqua SAW: Estrogen receptors in breast cancer therapy. Sci Am Sci Med 3:32–41, 1996

    Google Scholar 

  4. Jordan VC, Murphy CS: Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 11:578–610, 1990

    Google Scholar 

  5. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529–1542, 1996

    Google Scholar 

  6. Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88:1543–1549, 1996

    Google Scholar 

  7. Jordan VC, Morrow M: Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 30A:1714–1721, 1994

    Google Scholar 

  8. Katzenellenbogen BS: Estrogen receptors: Bioactivities and interactions with cell signaling pathways. Biol Reprod 54:287–293, 1996

    Google Scholar 

  9. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS: Tripartite steroid hormone receptor pharmacology. Interaction with multiple effector sites as a basis for the cell-and promoter-specific action of these hormones. Mol Endocrinol 10:119–131, 1996

    Google Scholar 

  10. Sarrel PM, Lufkin EG, Oursler MJ, Keefe D: Estrogen actions in arteries, bone and brain. Sci Am Sci Med 1:44–53, 1994

    Google Scholar 

  11. Kneifel MA, Katzenellenbogen BS: Comparative effects of estrogen and antiestrogen on plasma renin substrate levels and hepatic estrogen receptors in the rat. Endocrinology 108:545–552, 1981

    Google Scholar 

  12. Toney TW, Katzenellenbogen BS: Anticstrogen action in the medial basal hypothalamus and pituitary of immature female rats: insights concerning relationships among estrogen, dopamine and prolactin. Endocrinology 119:2661–2669, 1986

    Google Scholar 

  13. Wakeling AE, Bowler J: Biology and mode of action of pure antiestrogens. J Steroid Biochem 30:141–147, 1988

    Google Scholar 

  14. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867–3873, 1991

    Google Scholar 

  15. Nique F, Van de Velde P, Bremaud J, Hardy M, Philibert D, Teutsch G: 11β-amidoalkoxyphenyl estradiols, a new series of pure antiestrogens. J Steroid Biochem Molec Biol 50:21–29, 1994

    Google Scholar 

  16. Nicholson RI, Gee JMW, Francis AB, Manning DL, Wakeling AE, Katzenellenbogen BS: Observations arising from the use of pure antioestrogens on oestrogen-responsive (MCF-7) and oestrogen growth-independent (K3) human breast cancer cells. Endocrine Related Cancer 2:115–121, 1995

    Google Scholar 

  17. Wakeling AE: The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res Treat 25:1–9, 1993

    Google Scholar 

  18. Sato M, Rippy, MK, Bryant HU: Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 10:905–912, 1996

    Google Scholar 

  19. Yang NN, Venugopalan M, Hardikar S, Glasebrook A: Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273:1222–1225, 1996

    Google Scholar 

  20. Berry M, Metzger D, Chambon P: Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9:2811–2818, 1990

    Google Scholar 

  21. Montano MM, Muller V, Trobaugh A, Katzenellenbogen BS: The carboxy terminal F-domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol 9:814–825, 1995

    Google Scholar 

  22. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP: Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:21–30, 1994

    Google Scholar 

  23. Kraus WL, McInerney EM, Katzenellenbogen BS: Ligand-dependent, transcriptionally productive association of the amino-and carboxyl-terminal regions of a steroid hormone nuclear receptor. Proc Natl Acad Sci USA 92:12314–12318, 1995

    Google Scholar 

  24. Tsai MJ, O'Malley BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451–486, 1994

    Google Scholar 

  25. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491–1494, 1995

    Google Scholar 

  26. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435–2446, 1995

    Google Scholar 

  27. Cho H, Katzenellenbogen BS: Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators. Molec Endocrinol 7:441–452, 1993.

    Google Scholar 

  28. Cho H, Aronica SM, Katzenellenbogen BS: Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic AMP, estradiol, IGF-1 and serum factors. Endocrinology 134:658–664, 1994

    Google Scholar 

  29. Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW, Washburn TF, McLachlan JA, Korach KS: Coupling of dual signaling pathways: Epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci USA 89:4658–4662, 1992

    Google Scholar 

  30. Groenemeyer H: Transcriptional regulation by estrogen and progesterone receptors. Annu Rev Genet 25:89–123, 1991

    Google Scholar 

  31. Montano MM, Müller V, Trobaugh A, Katzenellenbogen BS: The carboxy-terminal F domain of the human estrogen receptor: Role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol 9:814–825, 1995

    Google Scholar 

  32. Read LD, Katzenellenbogen BS: Characterization and regulation of estrogen and progesterone receptors in breast cancer. In: Dickson RB, Lippman ME (eds) Genes, Oncogenes and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer. Kluwer Academic Publishers, Boston, 1991, pp 277–299

    Google Scholar 

  33. Dickson RB, Lippman ME: Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 8:29–43, 1987

    Google Scholar 

  34. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417–428, 1987

    Google Scholar 

  35. Knabbe C, Zugmaier G, Schmahl M, Dietel M, Lippman ME, Dickson RB: Induction of transforming growth factor β by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am J Clin Oncol (CCT) 14(Suppl 2):S15–S20, 1991

    Google Scholar 

  36. Vignon F, Bouton MM, Rochefort H: Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem Biophys Res Commun 146:1502–1508, 1987

    Google Scholar 

  37. Katzenellenbogen BS, Norman MJ: Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: Interrelationships among insulin/IGF-1, serum and estrogen. Endocrinology 126:891–898, 1990

    Google Scholar 

  38. Dauvois S, Danielian PS, White R, Parker MG: Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing turnover. Proc Natl Acad Sci USA 89:4037–4041, 1992

    Google Scholar 

  39. Montano MM, Ekena KE, Krueger KD, Keller AL, Katzenellenbogen BS: Human estrogen receptor ligand activity inversion mutants: Receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol 10:230–242, 1996

    Google Scholar 

  40. Haran EF, Maratzek AF, Goldberg I, Horwitz A, Degani H: Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res 54:5511–5514, 1994

    Google Scholar 

  41. McCloskey DE, Armstrong DK, Jackisch C, Davidson NE: Programmed cell death in human breast cancer cells. Recent Prog Horm Res 51:493–508, 1996

    Google Scholar 

  42. Jensen RA, Thompson ME, Jetton TL, Szabo CI, van der Meer R, Helou B, Tronick SR, Page DL, King MC, Holt JT: BRCA1 is scercted and exhibits properties of a granin. Nature Genetics 12:303–308, 1996

    Google Scholar 

  43. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925–5930, 1996

    Google Scholar 

  44. Mosselman S, Polman J, Dijkema R: ERβ: identification and characterization of a novel human estrogen receptor. FEBS Letters 392:49–53, 1996

    Google Scholar 

  45. Pakdel F, Katzenellenbogen BS: Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination. J Biol Chem 267:3429–3437, 1992

    Google Scholar 

  46. Wrenn CK, Katzenellenbogen BS: Structure function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast. J Biol Chem 268:24089–24098, 1993

    Google Scholar 

  47. Katzenellenbogen BS, Bhardwaj B, Fang H, Ince BA, Pakdel F, Reese JC, Schodin DJ, Wrenn CK: Hormone binding and transcription activation by estrogen receptors: Analyses using mammalian and yeast systems. J Steroid Biochem Molec Biol 47:39–48, 1993

    Google Scholar 

  48. Fawell SE, Lees JA, White R, Parker MG: Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell 60:953–962, 1990

    Google Scholar 

  49. Danielian PS, White R, Hoare SA, Fawell SF, Parker MG: Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol Endocrinol 7:232–240, 1993

    Google Scholar 

  50. Reese JC, Katzenellenbogen BS: Characterization of a temperature-sensitive mutation in the hormone binding domain of the human estrogen receptor: Studies in cell extracts and intact cells and their implications for hormone-dependent transcriptional activation. J Biol Chem 267:9868–9873, 1992

    Google Scholar 

  51. Ekena KE, Weis KE, Katzenellenbogen JA, Katzenellenbogen BS: Identification of amino acids in the hormone binding domain of the human estrogen receptor important in estrogen binding. J Biol Chem 271:20053–20059, 1996

    Google Scholar 

  52. Ekena K, Weis KE, Katzenellenbogen JA, Katzenellenbogen BS: Different residues of the human estrogen receptor are involved in the recognition of structurally diverse estrogens and antiestrogens. J Biol Chem 272:5069–5075, 1997

    Google Scholar 

  53. Allan GF, Leng XH, Tsai SY, Weigel NL, Edwards DP, Tsai M-J, O'Malley BW: Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 267:19513–19520 1992

    Google Scholar 

  54. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW: Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659–669, 1995

    Google Scholar 

  55. Fujimoto N, Katzenellenbogen BS: Alteration in the agonist/antagonist halance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: Antiestrogen-selectivity and promoter-dependence. Mol Endocrinol 8:296–304, 1994

    Google Scholar 

  56. Oñate SA, Tsai SY, Tsai M-J, O'Malley BW: Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354–1357, 1995

    Google Scholar 

  57. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M: Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264:1455–1458, 1994

    Google Scholar 

  58. Cavaillés V, Dauvois S, Danielian PS, Parker MG: Interaction of proteins with transcriptionally active estrogen receptors. Proc Natl Acad Sci USA 91:10009–10013, 1994

    Google Scholar 

  59. Weis KE, Ekena K, Thomas JA, Lazennec G, Katzenellenbogen BS: Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol 10:1388–1398, 1996

    Google Scholar 

  60. McInerney EM, Katzenellenbogen BS: Different regions in activation function-1 of the human estrogen receptor required for antiestrogen-dependent and estradiol-dependent transcription activation. J Biol Chem 271:24172–24178, 1996

    Google Scholar 

  61. McInerney EM, Tsai MJ, O'Malley BW, Katzenellenbogen BS: Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc Natl Acad Sci USA 93:10069–10073, 1996

    Google Scholar 

  62. Katzenellenbogen BS: Antiestrogen resistance: Mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. J Natl Cancer Inst 83:1434–1435, 1991

    Google Scholar 

  63. Touchette N: Tamoxifen resistance in breast cancer. J NIH Research 4:67–72, 1992

    Google Scholar 

  64. McGuire WL, Chamness GC, Fuqua SAW: Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5:1571–1577, 1991

    Google Scholar 

  65. Miksicek RJ, Lei Y, Wang Y: Exon skipping gives rise to alternatively spliced forms of the estrogen receptor in breast tumor cells. Breast Cancer Res Treat 26:163–174, 1993

    Google Scholar 

  66. Fuqua SAW, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, O'Malley BW, Greene GL, McGuire WL: Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 52:483–486, 1992

    Google Scholar 

  67. Garcia T, Sanchez M, Cox JL, Shaw PA, Ross JBA, Lehrer S, Schachter B: Identification of a variant form of the human estrogen receptor with an amino acid replacement. Nucleic Acids Res 17:8364–8368, 1989

    Google Scholar 

  68. Murphy LC, Dotzlaw H: Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples. Mol Endocrinol 3:687–693, 1989

    Google Scholar 

  69. McGuire WL, Chamness GC, Fuqua SAW: The importance of normal and abnormal oestrogen receptor in breast cancer. Cancer Surveys 14:31–40, 1992

    Google Scholar 

  70. Fuqua SAW, Chamness GC, McGuire WL: Estrogen receptor mutations in breast cancer. J Cell Biochem 51:135–139, 1993

    Google Scholar 

  71. Castles CG, Fuqua SAW: Alterations within the estrogen receptor in breast cancer. In: Pasqualini JR, Katzenellenbogen BS (eds) Hormone Dependent Cancer. Marcel Dekker, New York, 1996, pp 81–105

    Google Scholar 

  72. Karnik PS, Kulkarni S, Liu X, Budd GT, Bukowski RM: Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 54:349–353, 1994

    Google Scholar 

  73. Herman ME, Katzenellenbogen BS: Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen. J Steroid Biochem Molec Biol 59:121–134, 1996

    Google Scholar 

  74. Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M. Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83:1477–1482, 1991

    Google Scholar 

  75. Scott GK, Kushner P, Vigne J-L, Benz CC: Truncated forms of DNA-binding estrogen receptors in human breast cancer. J Clin Invest 88:700–706, 1991

    Google Scholar 

  76. Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W: Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 92:4206–4210, 1995

    Google Scholar 

  77. Wolf DM, Jordan VC: The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 31:129–138, 1994

    Google Scholar 

  78. Pakdel F, Reese JC, Katzenellenbogen BS: Identification of charged residues in an N-terminal portion of the hormone binding domain of the human estrogen receptor important in transcriptional activity of the receptor. Mol Endocrinol 7:1408–1417, 1993

    Google Scholar 

  79. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y: Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47:4355–4360, 1987

    Google Scholar 

  80. Clarke R, Brünner N, Katzenellenbogen BS, Thompson EW, Norman MJ, Koppi C, Soonmyoung P, Lippman ME, Dickson RB: Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci USA 86:3649–3653, 1989

    Google Scholar 

  81. Jiang S, Wolf DM, Yingling JM, Chang C, Jordan VC: An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol 90:77–86, 1992

    Google Scholar 

  82. Vassilomanolakis ME, Tsoussis S, Kandylis K, Hajichristou E, Efredmidis AP: Rechallenge by tamoxifen in metastatic breast cancer: Prospective study of different dose levels. Breast Dis 4:129–134, 1991

    Google Scholar 

  83. Stoll BA: Intermittent antiestrogen therapy in advanced breast cancer. Cancer Treat Rep 67:98, 1983

    Google Scholar 

  84. Stoll BA: Rechallenging breast cancer with tamoxifen therapy. Clin Oncol 9:347–351, 1983

    Google Scholar 

  85. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS: Phosphorylation of the human estrogen receptor: Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 269:4458–4466, 1994

    Google Scholar 

  86. Minton JP, Wisenbaugh T, Matthews RH: Elevated cyclic AMP levels in human breast-cancer tissue. J Natl Cancer Inst 53:283, 1974

    Google Scholar 

  87. Cohen LA, Chan P: Intracellular cAMP levels in normal rat mammary gland and adenocarcinoma: In vivo vs, in vitro. Life Sci 16:107–115, 1974

    Google Scholar 

  88. Miller WR, Elton RA, Dixon JM, Chetty U, Watson DMA: Cyclic AMP binding proteins and prognosis in breast cancer. Br J Cancer 61:263–266, 1990

    Google Scholar 

  89. Miller WR, Watson DMA, Jack W, Chetty U, Elton RA: Tumour cyclic AMP binding proteins: An independent prognostic factor for disease recurrence and survival in breast cancer. Breast Cancer Res Treat 26:89–94, 1993

    Google Scholar 

  90. Kvinnsland S, Ekanger R, Døskeland SO, Thorsen T: Relationship of cyclic AMP binding capacity and estrogen receptor to hormone sensitivity in human breast cancer. Breast Cancer Res Treat 3:67–72, 1983

    Google Scholar 

  91. Watson DMA, Hawkins RA, Bundred NJ, Stewart HJ, Miller WR: Tumour cyclic AMP binding proteins and endocrine responsiveness in patients with inoperable breast cancer. Br J Cancer 56:141–142, 1987

    Google Scholar 

  92. Gottardis MM, Jordan VC: Development of tamoxifenstimulated growth of MCF-7 tumors in athymic mice atter long-term antiestrogen administration. Cancer Res 48:5183–5187, 1988

    Google Scholar 

  93. Osborne CK: Tamoxifen metabolism as a mechanism for resistance. Endocrine-Related Cancer 2:53–58, 1995

    Google Scholar 

  94. Howell A, DeFriend D, Robertson J, Blamey R, Walton P: Response to a specific antiestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345:29–30, 1995

    Google Scholar 

  95. Hu XF, Veroni M, De Luise M, Wakeling A, Sutherland R, Watts CKW, Zalcberg JR: Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int J Cancer 55:873–876, 1993

    Google Scholar 

  96. Wakeling A: Physiological effects of pure antiestrogens. In: Pasqualini JR, Katzenellenbogen BS (eds) Hormone Dependent Cancer. Marcel Dekker, New York, 1996, pp 107–115

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular and Integrative Physiology, University of Illinois and University of Illinois College of Medicine, Urbana, IL, 61801-3704, USA

    Benita S. Katzenellenbogen, Monica M. Montano, Kirk Ekena, Mary E. Herman & Eileen M. McInerney

  2. Cell and Structural Biology, University of Illinois and University of Illinois College of Medicine, Urbana, IL, 61801-3704, USA

    Benita S. Katzenellenbogen, Monica M. Montano, Kirk Ekena, Mary E. Herman & Eileen M. McInerney

Authors
  1. Benita S. Katzenellenbogen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica M. Montano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kirk Ekena
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mary E. Herman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eileen M. McInerney
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Katzenellenbogen, B.S., Montano, M.M., Ekena, K. et al. Antiestrogens: Mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 44, 23–38 (1997). https://doi.org/10.1023/A:1005835428423

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005835428423

Search

Navigation